注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗类风湿关节炎的效果研究

Effect of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ : IgG Fc Fusion Protein for Injection combined with methotrexate on rheumatoid arthritis

目的探究注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗类风湿关节炎的效果。方法选择2013年1月—2016年12月攀枝花市中心医院收治的类风湿关节炎患者87例为研究对象,随机将其分为42例的对照组(经甲氨蝶呤治疗)和45例的观察组(经注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗),对比两组患者的临床指标、炎性指标和血清炎症因子水平。结果治疗前,两组患者的晨僵、关节疼痛数、20 m步行时间均无差异;治疗后,两组患者的上述指标均比治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗前,两组患者的炎性指标类风温因子(RF)、血沉(ESR)及C反应蛋白(CRP)均无差异;治疗后,两组患者的上述指标均比治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗前,两组患者的血清炎症因子水平白介素-6(IL-6)、白介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)均无差异;治疗后,两组患者的IL-6、TNF-α标均比治疗前显著降低,IL-10比治疗前显著升高(P<0.05),且观察组显著优于对照组(P<0.05)。结论注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤可有效改善类风湿关节炎患者的临床指标、血清炎症因子水平和炎性指标,临床应用价值较高。

Objective To explore the efficacy of Yisaipu in combination with methotrexate in the treatment of rheumatoid arthritis.Methods We selected 87 patients with rheumatoid arthritis who were admitted to our hospital from January 2013 to December 2016 as research subjects.They were randomly divided into a control group of 42 patients(treated with methotrexate)and a study group of45 patients(treated with Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection plus methotrexate).The clinical parameters,inflammatory markers and serum inflammatory factors were compared between the two groups.Results Before treatment,there was no difference in morning stiffness,joint pain,and 20 m walking time between the two groups.After treatment,the above indicators of both groups were lower than before treatment,and the study group was more significant.Before treatment,the RF,ESR,and CRP levels of rheumatoid arthritis were not different between the two groups.After treatment,the above indicators of both groups were lower than before treatment,and the study group was more significant.Before treatment,serum IL-6,IL-10,and TNF-αlevels were not different between the two groups.After treatment,both IL-6 and TNNF-αlevels were higher than before treatment in both groups.With a decrease,IL-10 was higher than before treatment,and the study group was more significant(P<0.05).Conclusion Recombinant Human Tumor Necrosis Factor-αReceptorⅡ:IgG Fc Fusion Protein for Injection combined with methotrexate can effectively improve clinical indicators,serum inflammatory factors and rheumatoid arthritis related indicators in patients with rheumatoid arthritis,and has higher clinical value.